Back to Browse Journals » Biologics: Targets and Therapy » Volume 3

HER2 breast cancer therapies: a review

Authors Conleth G Murphy, Shanu Modi

Published Date June 2009 Volume 2009:3 Pages 289—301

DOI http://dx.doi.org/10.2147/BTT.S3479

Published 11 June 2009

Conleth G Murphy, Shanu Modi

Breast Cancer Medicine Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Abstract: Amplification of the HER2 gene and/or overexpression of its protein product have been found in up to 25% to 30% of human breast cancers and have been shown to be associated with poorer outcomes compared to ‘HER2 normal’ breast cancer. Research has focused on developing therapies directed to the HER2 receptor and its pathway. These include the monoclonal antibody trastuzumab, which has improved outcomes when used in patients with both advanced and early breast cancer. Lapatinib is a small-molecule tyrosine kinase inhibitor which has demonstrated activity in advanced breast cancer and is currently being evaluated in early stage disease. We discuss the therapeutic rationale and clinical trial experience with these agents. Other novel and emerging strategies targeting the HER2 receptor and its pathway are also discussed. These strategies include novel HER2 antibodies and small-molecule inhibitors, antibody–drug conjugates, agents targeting downstream components of the HER2 signaling pathway, and heat shock protein 90 (HSP90) inhibitors.

Keywords: HER2, human epidermal growth factor receptor 2, breast cancer, trastuzumab, lapatinib

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Self-assembled mPEG–PCL-g–PEI micelles for simultaneous codelivery of chemotherapeutic drugs and DNA: synthesis and characterization in vitro

Shi S, Zhu XC, Guo QF, Wang YJ, Zuo T, Luo F, Qian ZY

International Journal of Nanomedicine 2012, 7:1749-1759

Published Date: 30 March 2012

Insight into 144 patients with ocular vascular events during VEGF antagonist injections

Mansour AM, Shahin M, Kofoed PK, Parodi MB, Shami M, Schwartz SG

Clinical Ophthalmology 2012, 6:343-363

Published Date: 6 March 2012

Critical appraisal of the role of davunetide in the treatment of progressive supranuclear palsy

Gold M, Lorenzl S, Stewart AJ, Morimoto BH, Williams DR, Gozes I

Neuropsychiatric Disease and Treatment 2012, 8:85-93

Published Date: 9 February 2012

Drug-resistant tuberculosis: emerging treatment options

Adhvaryu MR, Vakharia BC

Clinical Pharmacology: Advances and Applications 2011, 3:51-67

Published Date: 14 December 2011

Interaction of curcumin nanoformulations with human plasma proteins and erythrocytes

Yallapu MM, Ebeling MC, Chauhan N, Jaggi M, Chauhan SC

International Journal of Nanomedicine 2011, 6:2779-2790

Published Date: 8 November 2011

Amino acid-responsive Crohn's disease: a case study

Alvin Stein, Marty Hinz, Thomas Uncini

Clinical and Experimental Gastroenterology 2010, 3:171-177

Published Date: 6 December 2010

Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia

Radhakrishnan Ramchandren, Charles A Schiffer

Biologics: Targets and Therapy 2009, 3:205-214

Published Date: 8 May 2009

Long-term pegylated interferon-α and its potential in the treatment of melanoma

Reinhard Dummer, Joanna Mangana

Biologics: Targets and Therapy 2009, 3:169-182

Published Date: 17 April 2009

Gene targeted therapeutics for liver disease in alpha-1 antitrypsin deficiency

Caitriona McLean, Catherine M Greene, Noel G McElvaney

Biologics: Targets and Therapy 2009, 3:63-75

Published Date: 21 January 2009